1. Home
  2. DNA vs DCTH Comparison

DNA vs DCTH Comparison

Compare DNA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

HOLD

Current Price

$9.17

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.70

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNA
DCTH
Founded
2008
1988
Country
United States
United States
Employees
485
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.8M
372.5M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
DNA
DCTH
Price
$9.17
$11.70
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$8.50
$22.00
AVG Volume (30 Days)
1.2M
520.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.37
$8.12
52 Week High
$17.58
$13.72

Technical Indicators

Market Signals
Indicator
DNA
DCTH
Relative Strength Index (RSI) 59.00 56.86
Support Level $7.59 $10.31
Resistance Level $10.27 $12.34
Average True Range (ATR) 0.74 0.58
MACD 0.01 0.08
Stochastic Oscillator 53.10 74.63

Price Performance

Historical Comparison
DNA
DCTH

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: